These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26181722)

  • 41. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital.
    Petrie S; Barras M; Lust K; Fagermo N; Allen J; Martin JH
    Intern Med J; 2016 Jul; 46(7):826-33. PubMed ID: 27087147
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.
    Sanchez-Pena P; Hulot JS; Urien S; Ankri A; Collet JP; Choussat R; Lechat P; Montalescot G
    Br J Clin Pharmacol; 2005 Oct; 60(4):364-73. PubMed ID: 16187968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IV enoxaparin in pediatric and cardiac ICU patients.
    Cies JJ; Santos L; Chopra A
    Pediatr Crit Care Med; 2014 Feb; 15(2):e95-103. PubMed ID: 24335994
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
    Malinoski D; Jafari F; Ewing T; Ardary C; Conniff H; Baje M; Kong A; Lekawa ME; Dolich MO; Cinat ME; Barrios C; Hoyt DB
    J Trauma; 2010 Apr; 68(4):874-80. PubMed ID: 20386282
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prolonged thromboprophylaxis with enoxaparin in early neurological rehabilitation.
    Lang A; Kienitz C; Wetzel P; Rollnik JD
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):470-5. PubMed ID: 20547551
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
    Bickford A; Majercik S; Bledsoe J; Smith K; Johnston R; Dickerson J; White T
    Am J Surg; 2013 Dec; 206(6):847-51, discussion 851-2. PubMed ID: 24070664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enoxaparin dosing in the elderly using adjusted body weight.
    Leri F; Voyce SJ; Scialla S; Glavich W; Dzielak E; Smego RA; Guzek J
    J Thromb Thrombolysis; 2009 Oct; 28(3):348-53. PubMed ID: 19283449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*.
    Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL
    Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
    Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
    Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
    Kurtoglu M; Koksoy C; Hasan E; Akcalı Y; Karabay O; Filizcan U;
    J Vasc Surg; 2010 Nov; 52(5):1262-70. PubMed ID: 20732787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
    Kopelman TR; O'Neill PJ; Pieri PG; Salomone JP; Hall ST; Quan A; Wells JR; Pressman MS
    Am J Surg; 2013 Dec; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
    Morishima Y; Honda Y; Kamisato C; Tsuji N; Kita A; Edo N; Shibano T
    Thromb Res; 2012 Sep; 130(3):514-9. PubMed ID: 22647432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
    Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA
    J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Arterial antithrombotic effects of aspirin, heparin, enoxaparin and clopidogrel alone, or in combination, in the rat.
    Daykin HJ; Sturgeon SA; Jones C; Wright CE
    Thromb Res; 2006; 118(6):755-62. PubMed ID: 16410020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease.
    Bontadelli J; Moeller A; Schmugge M; Schraner T; Kretschmar O; Bauersfeld U; Bernet-Buettiker V; Albisetti M
    Intensive Care Med; 2007 Nov; 33(11):1978-84. PubMed ID: 17554520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW; Lee JJ
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.